Introduction {#tca12979-sec-0005}
============

Lung cancer is the leading cause of cancer‐related death worldwide. Non‐small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.[1](#tca12979-bib-0001){ref-type="ref"} Half of lung cancer patients will have several metastases at diagnosis.[2](#tca12979-bib-0002){ref-type="ref"} In recent years, several investigations have revealed the oncogenic mechanisms caused by driver gene mutations that are associated with lung cancer. Epidermal growth factor receptor gene (*EGFR*) mutation, such as exon 19 deletions or exon 21 point mutation (L858R), is one of the driver gene mutations that is present in approximately 50% of NSCLCs in the East Asian populations.[3](#tca12979-bib-0003){ref-type="ref"} These mutations increase the kinase activity of EGFR, leading to hyperactivation of downstream survival signaling pathways.[4](#tca12979-bib-0004){ref-type="ref"} In a previous study, \>85% of *EGFR*‐mutant NSCLC patients had exon 19 deletion or exon 21 L858R detected,[5](#tca12979-bib-0005){ref-type="ref"} which are called "common *EGFR* mutations."

NSCLC with common *EGFR* mutations markedly respond to first‐generation EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs) compared with platinum‐based chemotherapy.[6](#tca12979-bib-0006){ref-type="ref"}, [7](#tca12979-bib-0007){ref-type="ref"} Despite EGFR‐TKIs being effective clinically, approximately 15% of patients have no survival benefit.[6](#tca12979-bib-0006){ref-type="ref"}, [8](#tca12979-bib-0008){ref-type="ref"} Although several prognosis factors have been reported, the metastatic site is one of the most important among these factors. Indeed, metastatic sites, such as the brain, bone, and liver, as well as pleural effusion, were reported as predictors of poor prognosis in advanced *EGFR*‐mutant NSCLC.[9](#tca12979-bib-0009){ref-type="ref"}, [10](#tca12979-bib-0010){ref-type="ref"}, [11](#tca12979-bib-0011){ref-type="ref"}, [12](#tca12979-bib-0012){ref-type="ref"}, [13](#tca12979-bib-0013){ref-type="ref"} Among these sites, the median overall survival (OS) was significantly shorter in patients with brain metastasis than in those without brain metastasis. Specifically, the presence of brain metastasis has been previously confirmed to be a prognosis factor in a multivariate analysis.[9](#tca12979-bib-0009){ref-type="ref"}

Although several studies have assessed the correlation between metastatic site and the prognosis of *EGFR*‐mutant NSCLC patients,[11](#tca12979-bib-0011){ref-type="ref"}, [12](#tca12979-bib-0012){ref-type="ref"}, [13](#tca12979-bib-0013){ref-type="ref"} they often included patients with brain metastasis, which is an independent factor for poor prognosis.[9](#tca12979-bib-0009){ref-type="ref"} Therefore, limited information is available regarding the prognosis factor of *EGFR*‐mutant NSCLC patients without brain metastasis. In this study, we aimed to clarify the impact on prognosis according to the metastatic site in common *EGFR*‐mutant NSCLC patients without brain metastasis at diagnosis.

Methods {#tca12979-sec-0006}
=======

Patients {#tca12979-sec-0007}
--------

We retrospectively enrolled chemotherapy‐naïve advanced or postoperative‐recurrent NSCLC patients without brain metastasis who were diagnosed based on histological or cytological examination at the Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, between January 2010 and March 2016. Distant metastatic sites were screened by positron emission tomography, computed tomography, and gadolinium‐enhanced magnetic resonance imaging for the brain at diagnosis. The eligibility criteria were: (i) patients with common *EGFR* mutations, such as exon 19 deletion or exon 21 L858R; (ii) patients treated with first‐generation EGFR‐TKI, such as gefitinib or erlotinib, as a first‐line therapy, until disease progression or unacceptable toxicities; and (iii) patients without brain metastasis confirmed by gadolinium‐enhanced magnetic resonance imaging at diagnosis.

Evaluation of patient characteristics {#tca12979-sec-0008}
-------------------------------------

Clinical parameters, such as age, sex, histological subtype, stage, *EGFR* mutation status, metastatic sites, Eastern Cooperative Oncology Group performance status (PS), smoking status, progression‐free survival (PFS), and OS, were retrospectively collected from medical records. We examined metastatic sites, such as the bone and liver, and pleural effusion confirmed by computed tomography at diagnosis. The study protocol was approved by the ethics committees of our hospital (No. 744). TNM factor was classified using the 7th edition of the TNM stage classification system.

Statistical analysis {#tca12979-sec-0009}
--------------------

Cox proportional hazards modeling, which used several factors of patient profiles, was used. To analyze PFS, the time‐to‐event was estimated using the Kaplan--Meier method and compared by the log--rank test. PFS was defined as the period from the initiation date of EGFR‐TKI treatment to the date of disease progression or death. OS was defined as the period from the initiation date of EGFR‐TKI treatment to the date of death. Prognostic factors for OS were identified using univariate and multivariate logistic regression analyses. We performed the multivariate analysis based on significant factors identified in the univariate analysis in this present study. All statistical analyses were performed using EZR for Windows, version 1.35 (Saitama Medical Center, Jichi Medical University, Saitama, Japan). All *P*‐values \<0.05 were considered statistically significant.

Results {#tca12979-sec-0010}
=======

Patients' characteristics {#tca12979-sec-0011}
-------------------------

Of the 63 advanced or postoperative‐recurrent *EGFR*‐mutant NSCLC patients receiving first‐generation EGFR‐TKI during the study period, 13 patients were excluded because of the presence of brain metastasis. A total of 50 *EGFR*‐mutant NSCLC patients were analyzed in this study. The median age was 74 years (range 38--88 years), 29 patients (58.0%) were women, 36 (72.0%) were never smokers, and 46 (92.0%) had a good PS, 0 and 1. The histological subtype of most patients was adenocarcinoma (98.0%), and 25 patients (50.0%) had an exon 19 deletion. As shown in Table [1](#tca12979-tbl-0001){ref-type="table"}, 17 patients had bone metastases, four had liver metastases, and 13 had pleural effusion. A metastasis in multiple organs was detected in five patients. Of 17 patients with bone metastases, eight (47.1%) received palliative radiotherapy and two (11.8%) received bone‐modifying agent therapy.

###### 

Patients' characteristics by metastatic site

                             All patients        Bone metastasis     Liver metastasis    Pleural effusion
  -------------------------- ------------------- ------------------- ------------------- --------------------
  Age (years)                74.0 (38.0--88.0)   72.0 (38.0--83.0)   71.0 (66.0--80.0)   80.00 (38.0--88.0)
  Sex                                                                                    
  Male                       21 (42.0)           7 (41.2)            2 (50.0)            5 (38.5)
  Female                     29 (58.0)           10 (58.8)           2 (50.0)            8 (61.5)
  Smoking status                                                                         
  Smoker                     14 (28.0)           6 (35.3)            3 (75.0)            2 (15.4)
  Non‐smoker                 36 (72.0)           11 (64.7)           1 (25.0)            11 (84.6)
  Performance status                                                                     
  0                          19 (38.0)           5 (29.4)            0 (0.0)             1 (7.7)
  1                          27 (54.0)           11 (64.7)           3 (75.0)            9 (69.2)
  2                          4 (8.0)             1 (5.9)             1 (25.0)            3 (23.1)
  Histological subtype                                                                   
  Adenocarcinoma             49 (98.0)           17 (100.0)          4 (100.0)           12 (92.3)
  Squamous cell carcinoma    1 (2.0)             0 (0.0)             0 (0.0)             1 (7.7)
  Stage                                                                                  
  IIIB                       1 (2.0)             0 (0.0)             0 (0.0)             0 (0.0)
  IV                         34 (68.0)           15 (88.2)           4 (100.0)           12 (92.3)
  Postoperative recurrence   15 (30.0)           2 (11.8)            0 (0.0)             1 (7.7)
  *EGFR* mutation status                                                                 
  Exon 19 deletion           25 (50.0)           7 (41.2)            3 (75.0)            6 (46.2)
  Exon 21 L858R              25 (50.0)           10 (58.8)           1 (25.0)            7 (53.8)
  EGFR‐TKI                                                                               
  Gefitinib                  47 (94.0)           15 (88.2)           4 (100.0)           13 (100.0)
  Erlotinib                  3 (6.0)             2 (11.8)            0 (0.0)             0 (0.0)
  No. metastatic organs                                                                  
  1                          45 (90.0)           15 (88.2)           2 (50.0)            13 (100.0)
  ≥2                         5 (10.0)            2 (11.8)            2 (50.0)            0 (0.0)

Patients' characteristics with pleural effusion {#tca12979-sec-0012}
-----------------------------------------------

In this study, 13 patients had pleural effusion. Among the 13 patients with pleural effusion, 10 patients acquired resistance to EGFR‐TKI during the period. Of them, seven patients developed disease progression in the pleural effusion, and three patients developed disease progression in the lung metastasis. There was no significant relationship between the presence and absence of pleural effusion in clinical features, including stage, liver metastasis, and bone metastasis (Table [2](#tca12979-tbl-0002){ref-type="table"}). There was only one *EGFR*‐mutant NSCLC patient with pleural effusion in whom an operation was performed; this was a 71‐years‐old woman who had had a right pneumonectomy 2 years previously who developed recurrence due to right malignant pleural effusion diagnosed by pleural effusion cytology. Therefore, we could not statistically analyze the relationship between the site of pleural effusion and the side of the lung among recurrent stage IV cases.

###### 

Relationship between the presence of pleural effusion and the associated clinical features

                             Pleural effusion               
  -------------------------- ------------------ ----------- -------
  Stage                                                     
  Stage IIIB or IV           12 (92.3)          23 (62.2)   0.076
  Postoperative recurrence   1 (7.7)            14 (37.8)   
  Liver metastasis                                          
  Absence                    11 (84.6)          35 (94.6)   0.275
  Presence                   2 (15.4)           2 (5.4)     
  Bone metastasis                                           
  Absence                    11 (84.6)          22 (59.5)   0.173
  Presence                   2 (15.4)           15 (40.5)   

OS and PFS {#tca12979-sec-0013}
----------

At the time of analysis, the median follow‐up time for *EGFR*‐mutant patients was 24.2 months (range 2.2--95.4 months). In all patients, the median PFS was 12.2 months (95% confidence interval \[CI\] 8.3--13.3 months), and the median OS was 32.5 months (95% CI 23.1--67.4 months; Fig [1](#tca12979-fig-0001){ref-type="fig"}). There was no significant difference in PFS and OS between patients with and without bone metastases (Fig [2](#tca12979-fig-0002){ref-type="fig"}a, Fig [3](#tca12979-fig-0003){ref-type="fig"}a). The median PFS was significantly shorter in patients with liver metastasis than in those without liver metastasis (12.9 months, \[95% CI 8.4--16.6\] vs. 5.1 months, 95% CI 2.3-- not evaluable[1](#tca12979-bib-0001){ref-type="ref"} hazard ratio \[HR\] 4.42, 95% CI 1.45--13.46, *P* = 0.004; Fig [2](#tca12979-fig-0002){ref-type="fig"}b). There was no significant difference in OS between patients with and without liver metastases (Fig [3](#tca12979-fig-0003){ref-type="fig"}b). The median PFS was significantly shorter in patients with pleural effusion than in those without pleural effusion (pleural effusion: 13.0 months, 95% CI 9.1--21.7 vs. 7.0 months, 95% CI 3.7--13.0, HR 2.29, 95% CI 1.11--4.73, *P* = 0.020; Fig. [2](#tca12979-fig-0002){ref-type="fig"}c). The median OS was significantly shorter in patients with pleural effusion than in those without pleural effusion (19.5 months, 95% CI 5.7--28.8 vs. 55.3 months, 95% CI 24.0--NE; HR 3.00, 95% CI 1.35--6.68, *P* = 0.005; Fig. [3](#tca12979-fig-0003){ref-type="fig"}c).

![Kaplan--Meier curves for (**a**) progression‐free survival (PFS) and (**b**) overall survival (OS) in *EGFR*‐mutant non‐small cell lung cancer patients. In all patients (*n* = 50), the median PFS was 12.2 months (95% confidence interval \[CI\] 8.3--13.3 months), and the median OS was 32.5 months (95% CI 23.1--67.4 months).](TCA-10-557-g007){#tca12979-fig-0001}

![Kaplan--Meier curves for progression‐free survival (PFS) according to the metastatic site in *EGFR*‐mutant non‐small cell lung cancer patients. (**a**) There was no significant difference in PFS between patients with and without bone metastasis (BM; *P* = 0.269). () With BM and () without BM. (**b**) The median PFS was significantly longer in patients with liver metastasis (LM) than in those without LM (5.1 months, 95% confidence interval \[CI\] 2.3--not evaluable, vs. 12.9 months, 95% CI 8.4--16.6; hazard ratio \[HR\] 4.42, 95% CI 1.45--13.46, *P* = 0.004). () With LM and () without LM. (**c**) The median PFS was significantly longer in patients with pleural effusion (PE) than in those without PE (7.0 months, 95% CI 3.7--13.0 vs. 13.0 months, 95% CI 9.1--21.7; HR 2.29, 95% CI 1.11--4.73, *P* = 0.020). (![](TCA-10-557-g004.jpg "image")) With PE and (![](TCA-10-557-g003.jpg "image")) without PE.](TCA-10-557-g006){#tca12979-fig-0002}

![Kaplan--Meier curves for overall survival (OS) according to the metastatic site in *EGFR*‐mutant non‐small cell lung cancer patients. (**a**,**b**) There was no significant difference in OS between patients with and without bone metastasis (BM) and liver metastasis (LM; *P* = 0.859, 0.600, respectively). () With BM, () without BM, () with LM and () without LM. (**c**) The median OS was significantly longer in patients with pleural effusion (PE) than in those without PE (19.5 months, 95% confidence interval (CI) 5.7--28.8 vs. 55.3 months, 95% CI 24.0--not evaluable; hazard ratio 3.00, 95% CI 1.35--6.68, *P* = 0.005). (![](TCA-10-557-g001.jpg "image")) With PE and (![](TCA-10-557-g002.jpg "image")) without PE.](TCA-10-557-g005){#tca12979-fig-0003}

As shown in Table [3](#tca12979-tbl-0003){ref-type="table"}, in the multivariate analysis, pleural effusion was an independent prognostic factor for poor PFS (HR 2.98, 95% CI 1.40--6.35, *P* = 0.005) and OS (HR 2.79, 95% CI 1.14--6.83, *P* = 0.025), although bone or liver metastases were not independent prognostic factors. Multiple metastatic sites was an independent prognostic factor for PFS (HR 12.60, 95% CI 2.18--72.96, *P* = 0.005),and poor OS (HR 4.94, 95% CI 1.23--19.87, *P* = 0.025).

###### 

Prognostic factors in *EGFR*‐mutant non‐small cell lung cancer patients without brain metastasis according to univariate and multivariate analyses

                                                                  Progression‐free survival   Overall survival                                                                                   
  --------------------------------------------------------------- --------------------------- ------------------ --------------------- ------- -------------------- ------- -------------------- -------
  Age (\<75/≥75 years)                                            0.70 (0.37--1.34)           0.281              ---                   ---      1.40 (0.66--2.98)   0.377   ---                  ---
  Sex (male/female)                                               1.32 (0.70--2.48)           0.395              ---                   ---      1.31 (0.62--2.78)   0.482   ---                  ---
  Performance status (0--1/2)                                     1.91 (0.45--7.99)           0.368              ---                   ---      1.94 (0.86--4.36)   0.104   ---                  ---
  Smoking status (smoker/never smoker)                            1.84 (0.91--3.71)           0.085              ---                   ---      0.94 (0.22--4.00)   0.938   ---                  ---
  Histological subtype (adenocarcinoma/squamous cell carcinoma)   0.17 (0.02--1.38)           0.059              ---                   ---      0.32 (0.04--2.43)   0.242   ---                  ---
  Stage (postoperative relapse/stage IIIB, IVA, IVB)              0.50 (0.24--1.02)           0.051              ---                   ---      0.32 (0.13--0.83)   0.014   0.49 (0.17--1.38)    0.175
  *EGFR* mutation status (exon 19 deletion/Exon 21 L858R)         0.84 (0.45--1.58)           0.593              ---                   ---      0.96 (0.45--2.02)   0.907   ---                  ---
  EGFR‐TKI (gefitinib/erlotinib)                                  1.67 (0.40--6.98)           0.478              ---                   ---        Not evaluable     0.080   ---                  ---
  No. metastatic organs (≥2/1)                                    6.49 (2.31--18.24)          \<0.001            12.60 (2.18--72.96)   0.005    4.12 (1.14--14.95)  0.020   4.94 (1.23--19.87)   0.025
  Bone metastasis (positive/negative)                             1.45 (0.75--2.80)           0.269              ---                   ---      1.08 (0.47--2.47)   0.859   ---                  ---
  Liver metastasis (positive/negative)                            4.42 (1.45--13.46)          0.004              0.66 (0.11--4.05)     0.656    3.84 (0.85--17.4)   0.060   ---                  ---
  Pleural effusion (positive/negative)                            2.29 (1.11--4.73)           0.020              2.98 (1.40--6.35)     0.005    3.00 (1.35--6.68)   0.005   2.79 (1.14--6.83)    0.025

Discussion {#tca12979-sec-0014}
==========

In this study, our multivariate analysis identified pleural effusion and the multiple metastatic organs associated with poorer PFS and OS in *EGFR*‐mutant NSCLC without brain metastasis.

Correspondingly, previous reports showed that the presence of pleural effusion was a significant poor prognosis factor in *EGFR*‐mutant NSCLC patients.[14](#tca12979-bib-0014){ref-type="ref"}, [15](#tca12979-bib-0015){ref-type="ref"} Pleural effusion was reported to be formed through vascular endothelial growth factor (VEGF) activity, which is associated with vascular hyperpermeability.[16](#tca12979-bib-0016){ref-type="ref"}, [17](#tca12979-bib-0017){ref-type="ref"}, [18](#tca12979-bib-0018){ref-type="ref"} In addition, the overexpression of VEGF receptors in tumors reduces the sensitivity to EGFR‐TKI.[19](#tca12979-bib-0019){ref-type="ref"} From these findings, EGFR‐TKI has little effect on *EGFR*‐mutant NSCLC patients with pleural effusion, and the combination therapy of anti‐VEGF therapy and EGFR‐TKI might be theoretically promising for the treatment of *EGFR*‐mutant NSCLC patients with pleural effusion. Indeed, several clinical trials showed that the combination therapy with erlotinib plus bevacizumab resulted in significantly longer PFS than EGFR‐TKI therapy alone in *EGFR*‐mutant NSCLC patients, including patients with pleural effusion.[20](#tca12979-bib-0020){ref-type="ref"}, [21](#tca12979-bib-0021){ref-type="ref"}, [22](#tca12979-bib-0022){ref-type="ref"} In addition, the previous study reported that the high levels of VEGF expression in NSCLC tissue were identified as an independent poor prognostic factor.[23](#tca12979-bib-0023){ref-type="ref"} Because VEGF levels in malignant pleural effusion caused by lung cancer were significantly higher than VEGF levels in benign exudative pleural effusion,[24](#tca12979-bib-0024){ref-type="ref"} *EGFR*‐mutant NSCLC patients with pleural effusion may have had a worse survival rate, consistent with our study result.

Because patients with brain metastasis were excluded from this study, our study results were different from those of previous studies. In particular, bone metastasis in *EGFR*‐mutant NSCLC, which was a poor prognosis factor in several reports, did not indicate a poor prognosis in this study.[12](#tca12979-bib-0012){ref-type="ref"}, [15](#tca12979-bib-0015){ref-type="ref"} Patients with bone metastasis might have prolonged survival due to radiotherapy and bone‐modifying agent therapy.[25](#tca12979-bib-0025){ref-type="ref"}, [26](#tca12979-bib-0026){ref-type="ref"} However, in the present study, not all patients with bone metastasis received these treatments, and there was no significant difference in prognosis between patients who received these treatments and those who did not (data not shown). As a result, these treatments might have little effect on prognosis in the present study. First‐generation EGFR‐TKI has a limited ability to penetrate the blood--brain barrier; the ratio of first‐generation EGFR‐TKI transformation to the brain was reported to be 1--3%.[27](#tca12979-bib-0027){ref-type="ref"} Therefore, the prognosis of *EGFR*‐mutant NSCLC patients with brain metastasis was considerably poor, as evidenced by the low response rate of 43% in the clinical trial.[28](#tca12979-bib-0028){ref-type="ref"} *EGFR*‐mutant NSCLC patients have a significantly higher incidence of brain and bone metastases.[11](#tca12979-bib-0011){ref-type="ref"}, [22](#tca12979-bib-0022){ref-type="ref"}, [28](#tca12979-bib-0028){ref-type="ref"}, [29](#tca12979-bib-0029){ref-type="ref"} Although the proportion of patients with bone and brain metastases were not described in these studies, 92.3% of patients with brain metastases also had bone metastases in the present study. Therefore, bone metastasis might be a factor of poor prognosis, because most *EGFR*‐mutant NSCLC patients might have both brain and bone metastases at diagnosis.

There were several limitations to our study. This study was a retrospective study conducted at a single institution with a small number of patients. In fact, although previous reports showed PS was the independent prognostic factor,[30](#tca12979-bib-0030){ref-type="ref"}, [31](#tca12979-bib-0031){ref-type="ref"} PS was not the prognostic factor in this study. However, metastasis to multiple organs was an independent poor prognostic factor in this study, which was consistent with the previous study.[32](#tca12979-bib-0032){ref-type="ref"} Therefore, further multi‐institutional studies are required to confirm our study results.

In conclusion, pleural effusion in advanced *EGFR*‐mutant NSCLC patients without brain metastasis was associated with a poorer PFS and OS. Further precision medicine according to the metastatic site is required.
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